D
Dixie Lee Esseltine
Researcher at Takeda Pharmaceutical Company
Publications - 55
Citations - 13474
Dixie Lee Esseltine is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 35, co-authored 55 publications receiving 12892 citations. Previous affiliations of Dixie Lee Esseltine include ImmunoGen, Inc. & Millennium Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Journal ArticleDOI
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more
TL;DR: Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
Journal ArticleDOI
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
Robert Z. Orlowski,Thomas E. Stinchcombe,Beverly S. Mitchell,Thomas C. Shea,Albert S. Baldwin,Stephanie Stahl,Julian Adams,Dixie Lee Esseltine,Peter J. Elliott,Christine S. Pien,Roberto Guerciolini,Jessica K. Anderson,Natalie D. Depcik-Smith,Rita Bhagat,Mary Jo Lehman,Steven C. Novick,Owen A. O'Connor,Steven L. Soignet +17 more
TL;DR: PS-341 showed activity against refractory multiple myeloma and possibly non-Hodgkin's lymphoma in this study, and merits further investigation in these populations.
Journal ArticleDOI
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,D. Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +14 more
TL;DR: Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.